key: cord-0771255-nhohnhfa
authors: Liu, Jian; Zhai, You; Liang, Lijun; Zhu, Danyan; Zhao, Qingwei; Qiu, Yunqing
title: Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
date: 2021-02-01
journal: Chem Phys
DOI: 10.1016/j.chemphys.2020.111080
sha: e9a32fffa752eb9c11cc6672f68390faaa392550
doc_id: 771255
cord_uid: nhohnhfa

Coronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (M(pro)) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 M(pro) were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stably to the COVID-19 M(pro) from the molecular dynamics simulation. Moreover, the MM/PBSA free energy calculations suggest that lopinavir with positive charge might be most active against COVID-19 M(pro).

The 2019 novel coronavirus (COVID-19) has spread rapidly worldwide [1] [2] [3] [4] [5] . Up to now (31 August 2020), COVID-19 has caused more than 840,000 deaths in the whole world, and confirmed infection cases have been reported more than 25,000,000 (https://covid19.who.int/). Unfortunately, the number of infection cases is still growing rapidly, but there are no approved effective drugs. Therefore, there is an urgent need for developing effective anti-COVID-19 drugs.

The COVID-19 is by far the most serious, but not the first coronavirus outbreak that endangers human health. As far as is known, including severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome-coronavirus (MERS-CoV) both have a huge impact on humans [6] [7] [8] [9] [10] . Currently, it was found that the main protease (M pro , also called 3CL pro ) plays a pivotal role in CoV (e.g., SARS-CoV and MERS-CoV) gene expression and replication [11] . M pro has been validated as an attractive target for anti-SARS-CoV and anti-MERS-CoV drug design, and a variety of inhibitors drugs have been developed [12] [13] [14] . More importantly, previous genome sequences analyses have revealed that COVID-19 share a high level of sequence similarity with the corresponding SARS-CoV and MERS-CoV [15] . Therefore, M pro is suggested to be an attractive target for anti-COVID-19 drug design, especially considering the re-use of existing MERS and SARS M pro inhibitors for COVID-19.

Recently, approved inhibitors including danoprevir [16] , darunavir [17] , ASC09

[ChiCTR2000029603], lopinavir/ritonavir [ChiCTR2000029539] have been reported to treat COVID-19 patients. At present, as an anti-HIV protease inhibitor, lopinavir/ritonavir has been widely used despite lack of sufficient efficacy data [18] . And the combination of lopinavir/ritonavir is a recommended antiviral regimen in the latest version of the Diagnosis and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China. However, it is debatable whether HIV protease inhibitors could effectively inhibit the COVID-19 M pro [19] . Moreover, inhibitors may have different tautomerization and protonation states, and the effects of different tautomeric and ionization states of inhibitors on their binding to protease are still unknown.

Molecular docking and molecular dynamics (MD) simulation have been confirmed as a powerful tool to understand the binding models of inhibitors to protease [20] [21] [22] [23] [24] . They have been successfully used to study the interaction between M pro and promising inhibitors. For example, Khan et al. found that several FDA approved anti-virus drugs can inhibit the function of M pro of COVID-19 [20] . Elfiky revealed that inhibitors such as ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir can bind tightly the RNA dependent RNA polymerase of COVID-19 [21] . However, the interaction details between M pro and some drugs that have participated in clinical trials are still scarce. In this study, five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) that have participated in clinical trials were selected for molecular docking analysis. As shown in Table 1 , the drug structures with different tautomeric and ionization states were pre-processed in Schrodinger software package using LigPrep [25] . Furthermore, based on docking scores, five filtered drug structures were subsequently imported into a detailed study through MD simulation and binding free energy calculation. 

The main protease (M pro ) with structure 6LU7 from the PDB [26] was prepared by Protein Preparation Wizard tool in Schrodinger software package. As shown in Table 1 , five drugs (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) were processed by Schrodinger's Lig-Prep module, and seven structures were chosen, which mainly includes prediction of protonation states and generation of three-dimensional conformation. The seven systems were named as DAN1/DAN2 (danoprevir with neutral/negative charge), DAR (darunavir), ASC1/ASC2 (ASC09 with two conformers), RIT (ritonavir) and LOP1/LOP2 (lopinavir with positive/neutral charge), respectively. The grid area for docking were determined according to original substrate coordinates in 6LU7 crystal structure. All other settings remained default, and the Glide docking was carried out with the standard precision (standard precision, SP) mode. Each molecule was retained at most 100 docking conformations.

All MD simulations were performed with GROMACS 5.0.7 package [27] , and the time-step was set to be 2 fs. CHARMM force field were used to parameterize the drugs and protein, respectively [28] . Each system was immersed in a periodic boundary conditions (PBC) box of TIP3P water, and the box size was 9.0 × 9.0 × 9.0 nm 3 . A rational number of counter ions (Na + or Cl -) were added to solution to neutralize the systems. In each system, the cut-off distance of van der Waals (vdW) interaction was set to be 1.2 nm. The cross interaction and electrostatic interactions between different atoms were calculated through Lorentz-Berthelot rule [29] and particle mesh Ewald (PME) method [30] , respectively. The velocity rescaling with a stochastic term [31] was used to keep system temperature at 300 K. The Berendsen method [32] was used to couple the pressure at 1 bar. In each system, a 50,000 step energy minimization was firstly performed, followed by a 200 ps preequilibration under an NVT ensemble. After energy minimization and pre-equilibration of the system, each simulation was conducted for 50 ns in NPT ensemble, where the last 10 ns were used for binding free energy calculation with using MM/PBSA method [33] . PyMOL software [34] was used for molecular visualization.

In the present study, a structure-based docking screening was According to the docking score, one system with strong binding strength was selected for each drug, and they are DAN1, DAR, ASC2, RIT and LOP1, respectively. Fig. 1 shows the probability density of docking scores for the five selected systems. One could find that the peak position of system LOP1 (lopinavir with positive charge) is around − 29.13 kJ/ mol, and the value is much lower than other compounds. The docking results indicated that lopinavir with positive charge showed highest binding affinity to compare with other compounds.

To estimate the stability of these compounds, the selected hits were subsequently imported into a detailed 50 ns MD simulation study. The Root Mean Square Deviation (RMSD) of drug molecules as a function of simulation time were displayed in Fig. 2 . It could be used to estimate the binding stability between drug molecules and protein. Fig. 2 showed that the RMSD value of all the systems were significantly stable with small deviation except for ASC1 system. It can be found that the overall RMSD value of ASC1 system (solid blue line) is ca. 3.0 Å, and it is highest to compare with other systems. It indicates that the binding stability of ASC1 system is weaker than other systems. Besides, the overall RMSD value of the other four systems is lower than 3 Å, and similar results have been shown by Khan et al. [20] . Specially, Khan et al. showed that the RMSD value of the system with Darunavir (DAR) is 2.59 Å, which is in according with the results from our study. Overall, the results from RMSD value indicate that most selected drugs can bind to the protein stably. The differences in stability between binding drugs and protein could also be reflected from the snapshots. As displayed in Fig. 3 , the formed hydrogen bonds between drugs and protein were shown in these systems. Fig. 3(a) showed that amino acid residues (e.g., PHE140, GLY143, CYS145, HIS164 and GLU166) play a key role in the original substrate binding, and it can form hydrogen bonding with the substrate. Besides, among these amino acid residues, GLU166 and GLN189 could form hydrogen bonding with most of selected drugs. A similar finding was previously reported by Xu et al. [35] , who revealed that residue GLU166 and GLN189 maintained the binding between drug nelfinavir and COVID-19 M pro . The results here indicate that the selected hits would stably bind to COVID-19 M pro in a similar way to that of the original substrate against COVID-19 M pro . The stability of these systems was also characterized by monitoring the Root Mean Square Fluctuation (RMSF) of protein residues. As shown in Fig. 4 , these systems have a quite similar RMSF fluctuation trend, and one could also found that most binding residues (e.g., ASN142, GLY143, GLU166, GLN189, etc., as shown in Fig. 3) were quite stable during the simulation. These observations further demonstrate that binding of selected hits stabilizes the COVID-19 M pro .

To provide insight into the binding mechanisms of the selected hits, the binding free energies (ΔG) were calculated by MM/PBSA method according to the equation (1),

where ΔE VDW and ΔE ele refer to van der Waals and electrostatic energy contributions, respectively. ΔGgb and ΔGnp represents polar and nonpolar desolvation free energies, respectively. TΔS refer to conformational entropy contribution at temperature T. As shown in Table 2 suggest that the electrostatic interaction play an important role in the binding of lopinavir. It mainly because of the strong electrostatic interaction between positively charged amine group of lopinavir and negatively charged residue of M pro (e.g., GLU166, as shown in Fig. 3(f) ). The binding free energy between all protein residues and selected drugs were calculated to provide more binding details. As shown in Fig. 5(a) , one could find that the residue GLU166 in LOP1 system make the most contribution to the binding free energy, and the value is much higher than other systems. Other negatively charged residues (e.g., GLU47, ASP48, ASP187) also make a great contribution to the binding free energy. Fig. 5 (b) shows that these negatively charged residues are close to positively charged lopinavir, and lopinavir is able to form hydrogen bonds with GLU166 and GLN189. The results suggest that lopinavir with positive charge might be active against COVID-19 M pro . Lopinavir/ritonavir may be a potential treatment option for COVID-19. Two studies showed the positive effects of lopinavir/ritonavir therapy [36, 37] . However, the efficacy of lopinavir/ ritonavir antiviral treatment warrants further verification in future studies.

In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 M pro were investigated by molecular docking, molecular dynamics simulation and free energy calculation. Based on the docking score, five drugs structures were selected for further evaluation. RMSD, RMSF, and typical snapshots of these systems suggest that most of the selected drugs can bind stably to the COVID-19 M pro in a similar way to that of the original substrate against COVID-19 M pro . Further MM/PBSA free energy calculations suggest that lopinavir with positive charge might be active against COVID-19 M pro . 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 5. (a) The bind free energy between all protein residues and selected five drugs. (b) Interaction details between negatively charged residues and positively charged lopinavir (LOP1 system). The data in red is the interaction distance (Å).

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

The continuing COVID-19 epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China

The novel coronavirus originating in Wuhan, China: challenges for global health governance

COVID-19: consider cytokine storm syndromes and immunosuppression

Virtually Perfect? Telemedicine for Covid-19

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-CoV

The proximal origin of SARS-CoV-2

Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

The SARS-CoV S glycoprotein: expression and functional characterization

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option

A new coronavirus associated with human respiratory disease in China

First clinical study using HCV protease inhibitor danoprevir to treat naive and experienced COVID-19 patients

Lack of antiviral activity of darunavir against SARS-CoV-2

Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Ul-Haq, Identification of chymotrypsinlike protease inhibitors of SARS-CoV-2 via integrated computational approach

Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2

Putative inhibitors of SARS-CoV-2 main protease from a library of marine natural products: A virtual screening and molecular modeling study

Pharmacophore Mapping of ligand based virtual screening, molecular docking and molecular dynamic simulation studies for finding potent NS2B/NS3 protease inhibitors as potential anti-dengue drug compounds

The crystal structure of COVID-19 main protease in complex with an inhibitor N3

GROMACS: fast, flexible, and free

CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields

Molecular theory of gases and liquids

Particle mesh Ewald: An N•log (N) method for Ewald sums in large systems

Canonical sampling through velocity rescaling

Molecular dynamics with coupling to an external bath

The PyMOL molecular graphics system, Version 2.0 Schrödinger, LLC

Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate− DNA helices

Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

This study was funded by the New Drug Creation Project of The 13th Five-Year National Science and Technology Major Special Project (2020ZX09201-003) and The Key R&D Plan Emergency Project of Zhejiang Science and Technology Department (2020C03123-8).